Hikal Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/t24hpjk9xwtygsceeblby1qw.pdf

Key Takeaways


The Warning Letter: Impact, Remediation & Customer Response

Manoj Mehrotra: "February is the right time to really approach them. And then if they believe that we are ready and we are able to convince them, then they come for a re-inspection. So, we will expect in maybe March, April, May, they should come for a re-inspection."

Pharmaceutical Business: CDMO, API & Animal Health

Sameer Hiremath: "No, I don't think, see, we are not catering to the basic contract research type of discovery. We are focusing on manufacturing led R&D, which is typically post-Phase 1. Late Phase 1, early Phase 2 is where we are getting involved in molecules."

Crop Protection & Specialty Chemicals

Sameer Hiremath: "I think that is going to be the differentiator for Hikal. And we are not trying to do the low-end, low-margin, commodity, large-volume. It is niche, medium-volume type of molecules for skincare products."

Capacity Build-Out & Asset Repurposing


Financials & Margin Walk


Guidance & Commitments

CommitmentSpecificsTimeline
FDA remediation plan completionOn track for completionDecember 2025
FDA re-inspection approachApproach US FDA; re-inspection if convinced of readinessApproach February 2026; re-inspection March-May 2026
Pharma revenue recoveryDeferred Rs. 80+ crores recognized; deliveries ramp up significantlyH2 FY26 (Q3 and Q4)
FY26 pharma growth guidanceStill working toward double-digit growth targetFY26
Crop protection recoveryGradual recovery; stable full-year performance similar to last yearH2 FY26
Personal care commercializationTwo to three products commercialized; plant commercialized by Q4; dispatches from next FYH2 FY26 / Q4 FY26
Development revenue from new customersAround $4-5 millionFY26
Key starting materials commercial launchCommercial launch of Phase III-advanced materialsFY27
Plant repurposement Phase 1Phase 1 completeQ4 FY26
Plant repurposement Phase 2Phase 2 completeEnd of calendar year (2026)
Major revenue from repurposed plantRevenue starts next FY; major revenueFY28 onwards
High-potency lab commercial suppliesCommercial supplies beginTwo to three years (FY28-FY29)
Food and nutraceutical peak outputReach peak outputWithin 18-24 months
FY27 characterizationTransition year; growth expected to returnFY28

Key Metrics

MetricQ2 FY26
Consolidated revenue₹319 cr, H1 FY26 at ₹699 cr
EBITDA₹8 cr, margin of 2.6%; H1 FY26 EBITDA ₹32 cr, margin 4.6%
Pharmaceutical segment revenue₹190 cr
Pharmaceutical segment EBIT₹(17) cr, margin negative 9.2%
Crop protection segment revenue₹129 cr
Crop protection segment EBIT₹(10) cr
Finance costs₹15 cr, down 13% YoY and 20% YoY
H1 FY26 capex₹65 cr, full-year guidance maintained at ₹200 cr
Debt-equity ratio0.55, improved from 0.59 at start of year
Revenue deferred to Q3₹80+ cr, pharma sales reversed from September and booked in October
CDMO revenue share~50% of total revenue
Pharma RFP conversion ratio15–20%, expected to improve to 20–25%
Development revenue from new CDMO customers$4–5 million expected in FY26
Remediation fixed cost impact₹8–10 cr added for US-based GMP consultants
US FDA re-inspection timelineMarch–May 2026 expected